---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-107288"
form_type: "8-K"
ticker: "AGEN"
cik: "0001098972"
company_name: "AGENUS INC"
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:24:19.373344+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Agenus reports $4.2M initial BOT+BAL revenue; net loss narrows to $3.1M in FY2025

## Summary
- Pre-commercial product revenue of $4.2M from early access programs in France and paid NPP across 30+ countries.
- BOT+BAL shows 42% two-year OS and ~21-month median OS in heavily pretreated MSS mCRC; Phase 3 BATTMAN trial initiated.
- France AAC expanded to ovarian cancer and sarcoma in January 2026; 200+ physician inquiries received globally.
- Zydus collaboration provided $91M upfront capital; $20M contingent payment triggered in March 2026 for manufacturing.
- Q4 2025 operating income $14.4M; full year net loss $3.1M vs prior year; other revenue $110M (non-cash royalty).

## SEC filing metadata
- accession: 0001193125-26-107288
- form_type: 8-K
- ticker: AGEN
- cik: 0001098972
- company_name: AGENUS INC
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1098972/000119312526107288/0001193125-26-107288-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1098972/000119312526107288/agen-20260316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-107288
- JSON: https://secwatch.observer/filing/0001193125-26-107288.json
- Plain text: https://secwatch.observer/filing/0001193125-26-107288.txt

## Key facts
- Earnings Releases
  AGENUS INC reported financial results for the fourth quarter ended December 31, 2025.
  - Period: the fourth quarter ended December 31, 2025
  - Result: reported results
  source text: On March 16, 2026, Agenus Inc. announced its financial results for the quarter and year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1098972/000119312526107288/0001193125-26-107288-index.htm
- Earnings Releases
  AGENUS INC reported financial results for the full year ended December 31, 2025.
  - Period: the full year ended December 31, 2025
  - Result: reported results
  source text: On March 16, 2026, Agenus Inc. announced its financial results for the quarter and year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1098972/000119312526107288/0001193125-26-107288-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.